Inhalation sciences: New Chairman brings extensive experience in respiratory clinical trials
(Stockholm, Sweden, June 5, 2020) On June 10[th] Inhalation Sciences’ new Chairman, Daniel Spasic, will chair his first Board meeting. The founder of a global CRO company which carried out numerous phase II and III clinical trials for respiratory treatments, his insights will be of crucial value to ISAB as PreciseInhale[®] heads towards clinical validation. So why did it take Spasic so long to accept the position? And what finally persuaded him?“I’d spent a lot of time in respiratory clinical research before, but not so much on the preclinical or in vitro, in vivo side,” Daniel Spasic says.